Artificial intelligence is becoming an increasingly important component of pharmaceutical research, with companies using machine learning to analyze complex biological data, identify drug targets and improve clinical development decisions. Against that backdrop, VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, announced a collaboration with AI-focused research partner Ardigen that is intended to strengthen development of the company’s BiTAC(R) oncology platform through AI-enabled target discovery and validation (https://ibn.fm/yoDH5).
Major pharmaceutical companies are expanding AI collaborations across oncology and immunology, recognizing AI’s potential to accelerate drug discovery and reduce costs. VERAXA’s partnership with Ardigen, a contract research organization specializing in artificial intelligence, computational biology and bioinformatics, aims to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while reducing development risks. The collaboration brings together VERAXA’s antibody engineering capabilities with Ardigen’s expertise, which has supported more than 700 discovery projects.
VERAXA’s Boolean “AND-gated” BiTAC(R) technology presents a use case that may be particularly well suited for AI-assisted target selection and therapeutic design. The technology is designed to activate T-cells only when two specific tumor-associated antigens are present, potentially improving selectivity and reducing off-target effects. AI analysis of historical clinical and preclinical datasets could help identify promising targets that were previously abandoned because of safety concerns, offering a second chance for therapies that were once deemed too risky.
The partnership reflects a broader trend toward combining computational biology with next-generation antibody therapeutics to improve research productivity. By leveraging AI, VERAXA aims to streamline the discovery of dual-target combinations that could lead to more effective cancer treatments with fewer side effects. Ardigen, headquartered in Kraków, Poland, with U.S. operations in San Francisco, brings deep expertise in machine learning and bioinformatics to the collaboration.
As AI continues to reshape the pharmaceutical landscape, companies like VERAXA that integrate AI into their core R&D processes may gain a competitive edge. The ability to rapidly analyze vast datasets and predict therapeutic outcomes could reduce the time and cost of bringing new cancer therapies to market. For VERAXA, the partnership with Ardigen represents a strategic move to harness AI’s potential in advancing its BiTAC(R) platform, potentially benefiting patients and investors alike.
For more information on VERAXA Biotech and its latest developments, visit the company’s newsroom at https://ibn.fm/VRXA.
